Tagged with Pricing

association The secretary general of the innovators’ association gives an overview of the current structural challenges facing the pharmaceutical industry in Turkey, and discusses the changes that need to be introduced for the vast potential of the Turkish pharmaceutical industry to be unlocked.   Could you give our readers a brief…

UCB UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan for regional expansion through partnerships. Given your patient centricity and UCB’s unique perspective, how would you assess the sectors approach…

association The CEO of Morocco’s oldest pharma association discusses the latest regulatory changes in Morocco and their impact on its members, as well as the position of Moroccan pharma in the African and European context. You have significant experience in the pharmaceutical industry in Morocco. What have been the key steps…

access The general manager of Iberma discusses the history of the Moroccan pharmaceutical industry, new measures to improve access, and working on Moroccan-European partnerships in the pharma sector. You have a long experience of the Moroccan pharmaceutical industry. What have been the most significant changes throughout its history? Morocco initiated its…

Servier The general manager of Servier Morocco reviews the situation of the market following the recent price cuts, how the local environment is changing with the rise of generics, and reveals his vision of creating a regional hub for Servier in Morocco. Today, Servier is number one in the Moroccan market for…

association Fatma Taman, Chair of ISPE and General Manager of PharmaVision, discusses the importance of proper education and training within the pharmaceutical industry to ensure the sector’s sustainable growth and development. Today we meet with you for the first time as the Chair of ISPE Turkey Affiliate; what have been your…

pricing The president and chairman of MC Pharma discusses the position of the pharmacy segment in the current Moroccan healthcare context.  Could you introduce MC Pharma to our international readers, and more especially describe the relationship that exists between MC Pharma and Cooper Pharma? MC Pharma was established in 2002 by…

Pfizer The country manager of Pfizer Morocco talks about the likelihood of Morocco becoming an African hub and why Pfizer is at the perfect size to play a key part in such a process, as well as how the country’s price decree hurt the multinational corporations.   Having been elected head of MIS…

generics At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses the company’s objectives for Spanish speaking Latin America and how it plans to leverage the recently acquired Bausch+Lomb business to…

MSD The managing director of MSD for Morocco, Tunisia, and French West Africa explains why the company has chosen Morocco as its hub for the region, discusses the difficulties associated with the government price cut and explains that pharma needs to focus on the local needs of the country.   Can…

pricing Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for optimizing a pharmaceutical firm’s performance in Argentina’s price-controlled, high inflation market. With the current inflationary pressures to reduce costs, why…

Novo Nordisk The global COO of the multinational at the forefront of the fight against diabetes explains why the Algerian market is so strategically important and how the ‘made in Algeria’ brand would have real potential at the regional level if only the government would remove impediments to export. As COO of Novo…